« Return to News | CROs/Service Providers

PRA Moves Headquarters To North Carolina

Monday, October 1, 2007 07:23 AM

PRA International plans to relocate its corporate headquarters from Reston, Va., to Raleigh, N.C. by the end of 2007. The move is to facilitate the CRO’s plans to grow the business. Presently only 37 employees are expected to be affected.

It stated the new location is closer to potential clients, has cost reduction benefits and the area has a strong talent pool of professionals. Starting in October, PRA stated it will begin increasing its staff levels in N.C. and hopes to hire 500 administrative and operations employees in the next five years.

PRA expects to take a charge of about $1.7 million due to the relocation.

"North Carolina has one of the fastest growing workforces in the United States and we are pleased to take advantage of the low employee turnover rate and the quality of life. We believe this move to Raleigh will position us well to achieve our future growth targets," stated Terrance Bieker, chief executive officer, PRA.

In a move that took PRA off the public market, the company was purchased in July by Genstar Capital, a private equity group based in San Francisco. The deal was valued at $790 million.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.